Dr. Michael Gibson
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Cancer
Studies Squamous Cell Carcinoma
17 reported clinical trials
36 drugs studied
About Michael Gibson
Education:
- Ph.D. in Clinical Investigation, Johns Hopkins Bloomberg School of Public Health, 2010.
- M.D., Johns Hopkins School of Medicine, Baltimore, Maryland, 1996.
- B.S., North Carolina State University, Raleigh, North Carolina, 1991.
Experience:
- Associate Professor of Medicine, Vanderbilt University.
- Director of Translational Research for Head and Neck Oncology, Vanderbilt-Ingram Cancer Center.
- Has held significant roles including Chairmanship at the Hillman Cancer Center Data, Safety and Monitoring Committee, and Medical Director of the University Hospitals Seidman Cancer Center Clinical Trials Unit.
- Renowned for advancing the treatment of aero-digestive cancers through translational research and clinical trials.
Area of expertise
1Cancer
Stage IV
Stage III
PD-L1 positive
2Squamous Cell Carcinoma
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Michael Gibson is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
More about Michael Gibson
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Michael Gibson has experience with
- Pembrolizumab
- Cisplatin
- Carboplatin
- Evorpacept
- Paclitaxel
- Radiation Therapy
Breakdown of trials Michael Gibson has run
Cancer
- A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Pembrolizumab + Radiation vs Chemotherapy + Radiation for Head and Neck Cancer
- Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
Squamous Cell Carcinoma
- A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Pembrolizumab + Radiation vs Chemotherapy + Radiation for Head and Neck Cancer
- Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Esophageal Cancer
Head and Neck Cancers
- A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Evorpacept + Immunotherapy + Chemotherapy for Head and Neck Cancer
- Evorpacept + Pembrolizumab for Head and Neck Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Gibson specialize in?
Michael Gibson focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael Gibson currently recruiting for clinical trials?
Yes, Michael Gibson is currently recruiting for 6 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Michael Gibson has studied deeply?
Yes, Michael Gibson has studied treatments such as Pembrolizumab, Cisplatin, Carboplatin.
What is the best way to schedule an appointment with Michael Gibson?
Apply for one of the trials that Michael Gibson is conducting.
What is the office address of Michael Gibson?
The office of Michael Gibson is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.